Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy

Toyoda, Hidenori; Yasuda, Satoshi; Shiota, Shohei; Kumada, Takashi; Tanaka, Junko

doi:10.1016/j.jiac.2021.08.018

Cited by 8 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the lower adherence of patients with HCV genotype 2b in our cohort might have been due to dropout of drug users, who are at high risk of HCV infection and reinfection, although there are relatively few drug users in Japan. Recently, we confirmed the complete lack of HCV reinfection in patients with SVR who continued regular follow-up after SVR [23]. By contrast, patients who drop out of post-SVR follow-up may be likely to experience HCV reinfection, which will be an important problem when addressing the complete elimination of HCV.…”

Section: Discussionsupporting

confidence: 56%

Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response

Toyoda

Yasuda

Shiota

et al. 2022

European Journal of Gastroenterology &Amp; Hepatology

Self Cite

View full text Add to dashboard Cite

Objective Patients with chronic hepatitis C virus (HCV) infection who achieve sustained virologic response (SVR) to anti-HCV therapy, that is the eradication of HCV, are recommended to continue regular hospital visits for the surveillance of hepatocellular carcinoma (HCC) that can develop after SVR. However, it is unclear how well patients with SVR adhere to post-SVR follow-up over the long term. We investigated this adherence and the factors associated with it. Methods Medical record data on regular hospital visits were reviewed in 1329 patients with no history of HCC who achieved SVR by anti-HCV therapy. At the time of SVR confirmation, all patients were advised to continue regular visits, and the risk of post-SVR HCC was explained. The adherence rate of post-SVR follow-up and associated factors were analyzed. Results Adherence rates decreased continuously over time, as follows: 76.6% at 5 years, 62.4% at 10 years, 48.8% at 15 years, and 35.3% at 20 years after SVR. Adherence rates did not differ based on the degree of baseline liver fibrosis and were significantly lower in patients who achieved SVR by interferon (IFN)-free therapy and those with HCV genotype 2b. Conclusion Adherence to post-SVR follow-up decreased over the long term, and rates differed by patient background. Adherence was especially poor in patients who achieved SVR by IFN-free therapy, and therefore, strategies are necessary to encourage these patients to maintain their regular schedule of hospital visits.

show abstract

Section: Discussionsupporting

confidence: 56%

Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response

Toyoda

Yasuda

Shiota

et al. 2022

European Journal of Gastroenterology &Amp; Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is unknown whether HCV reinfection in patients with prior HCV infection is more likely than initial HCV infection in previously uninfected patients. In a study from Japan, measurements of serum HCV RNA (a total of 23 187 HCV RNA tests) revealed no cases of HCV reinfection among 1329 patients with cured HCV who continued regular hospital visits for more than 10 years after completing anti‐HCV therapy [33] (Table 2). This indicates a very low likelihood of HCV reinfection, but the study focused on patients who were adherent with their hospital visits.…”

Section: How Will Oral Anti‐hcv Therapy Affect the Clinical Care Of H...mentioning

confidence: 99%

Management of dialysis patients with hepatitis C virus in the era of direct‐acting antiviral therapy

Toyoda

Kikuchi²

2023

Ther Apher Dial

Self Cite

View full text Add to dashboard Cite

The clinical use of direct‐acting antivirals (DAAs) for hepatitis C virus (HCV) infection has dramatically changed management of patients with HCV liver disease since 2014; this is also true for patients undergoing dialysis. Due to the high tolerability and antiviral efficacy of anti‐HCV therapy, most dialysis patients with HCV infection should currently be candidates for this treatment. Many patients with HCV antibodies no longer have HCV infection, and it is difficult to identify patients with actual HCV infection based only on HCV antibody assays. Despite the high rate of successful HCV eradication, the risk of liver‐related events such as hepatocellular carcinoma (HCC), the major complication of HCV infection, persists even after HCV cure, and patients at risk of HCC should undergo continuous HCC surveillance. Finally, the rarity of HCV reinfection and the survival benefit of HCV eradication in dialysis patients should be explored in further studies.

show abstract

“…El seguimiento a 1392 pacientes con RVS se realizó mediante carga viral en una muestra obtenida cada 6 meses. Del total de pacientes en seguimiento, 434 pacientes (31,2%) continuaron con las visitas regulares por más de 10 años; ninguno de los pacientes del seguimiento fue positivo durante el estudio, lo que evidencia la importancia de una vigilancia clínica estricta (46) . La estrategia ideal de prevención de la infección por VHC es la vacunación; sin embargo, los diferentes mecanismos del VHC de evasión de la respuesta inmune, incluida la variabilidad genética, han sido un gran impedimento para el desarrollo de una vacuna (21)(22)(23) .…”

Section: Prevención De Reinfección Por Hepatitis Cunclassified

Reinfección por virus de la hepatitis C: revisión de tema y presentación de un caso

Palmett

Uran-Velasquez

Orrego³

et al. 2022

Rev. colomb. Gastroenterol.

View full text Add to dashboard Cite

La infección crónica por el virus de la hepatitis C (VHC) afecta a 58 millones de personas y es una importante causa de morbimortalidad alrededor del mundo. La reinfección por VHC es un problema creciente en personas con factores de riesgo como consumo pesado de alcohol, sexo anal, sexo grupal y compartir agujas y jeringas; este tipo de infección se define como un nuevo contagio de VHC con un genotipo viral diferente al de la primera infección en un paciente luego de lograr una respuesta viral sostenida (RVS). La reinfección se presenta, en parte, debido a la ausencia de estrategias de promoción y prevención. Teniendo en cuenta estos antecedentes, se han propuesto estrategias más pragmáticas para controlar la infección por VHC y evitar la reinfección, tales como la microeliminación. En el presente artículo se presenta un caso de un paciente que presenta alteración en los marcadores de la bioquímica hepática, por lo que se solicita una prueba diagnóstica de infección por VHC y luego genotipificación viral, y se evidenció una infección por VHC genotipo 1, subgenotipo 1A. Se inició el manejo con antivirales de acción directa y se documentó una adecuada RVS12. Tres meses después el paciente regresó a consulta y en los exámenes de control se evidenció una carga viral elevada de VHC, por lo que se solicitó genotipificación y se demostró una nueva infección por VHC genotipo 4.

show abstract

Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy

Cited by 8 publications

References 9 publications

Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response

Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response

Management of dialysis patients with hepatitis C virus in the era of direct‐acting antiviral therapy

Reinfección por virus de la hepatitis C: revisión de tema y presentación de un caso

Contact Info

Product

Resources

About